@ARTICLE{
author={Tomczak Piotr,Popovic Lazar S,Barthelemy Philippe,Janicic Aleksander,Fernandez Elena Sevillano,Borchiellini Delphine,Aglietta Massimo,Maroto Jose,Carnot Aurelien,O'Connell Brenda,Zizlsperger Nora,Zhang Halle Huihong,Valderrama Begona P},
year={2021},
title={Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={6},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Hudes Gary,Carducci Michael,Tomczak Piotr,Dutcher Janice,Figlin Robert,Kapoor Anil,Staroslawska Elzbieta,Sosman Jeffrey,McDermott David,Bodrogi Istvan,Kovacevic Zoran,Lesovoy Vladimir,Schmidt-Wolf Ingo GH,Barbarash Olga,Gokm},
year={2007},
title={Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma},
journal={NEW ENGLAND JOURNAL OF MEDICINE},
volume={356},
number={22},
pages={2271-2281},
document_type={Article},
}